Vident Advisory LLC Raises Stock Holdings in Lantheus Holdings, Inc. $LNTH

Key Points

• Vident Advisory LLC significantly increased its stake in Lantheus Holdings, Inc. by 1,610.9%, acquiring a total of 47,427 shares, valued at approximately $4.6 million.
• Insider Rajiv A. Patel sold 3.36 million shares of Lantheus stock for around $189 million, representing a 49.18% decrease in his holdings.
• Analysts have mixed ratings for Lantheus, with an average target price of $105.50 and ratings ranging from "buy" to "hold".

Vident Advisory LLC boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 1,610.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,427 shares of the medical equipment provider's stock after buying an additional 44,655 shares during the period. Vident Advisory LLC owned 0.07% of Lantheus worth $4,629,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in LNTH. Stifel Financial Corp increased its stake in Lantheus by 14.3% during the 4th quarter. Stifel Financial Corp now owns 38,497 shares of the medical equipment provider's stock worth $3,444,000 after buying an additional 4,816 shares during the period. Northern Trust Corp grew its stake in shares of Lantheus by 11.7% in the 4th quarter. Northern Trust Corp now owns 916,384 shares of the medical equipment provider's stock valued at $81,980,000 after purchasing an additional 96,275 shares during the last quarter. Lido Advisors LLC purchased a new stake in shares of Lantheus during the 4th quarter worth approximately $1,366,000. Schonfeld Strategic Advisors LLC increased its stake in shares of Lantheus by 128.3% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 6,000 shares of the medical equipment provider's stock worth $537,000 after purchasing an additional 3,372 shares in the last quarter. Finally, Freestone Grove Partners LP purchased a new position in shares of Lantheus during the fourth quarter valued at approximately $535,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. B. Riley decreased their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Truist Financial set a $63.00 price target on Lantheus and gave the company a "hold" rating in a report on Monday, August 11th. Mizuho decreased their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, JMP Securities cut their target price on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Lantheus has an average rating of "Moderate Buy" and an average target price of $105.50.

Insider Activity

In other news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,838,066 shares of company stock worth $384,430,031. Insiders own 1.50% of the company's stock.

Lantheus Price Performance

Shares of LNTH stock opened at $54.90 on Friday. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The stock has a market cap of $3.73 billion, a PE ratio of 14.60 and a beta of 0.14. The firm's 50 day moving average price is $69.20 and its two-hundred day moving average price is $83.19.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. During the same period in the previous year, the firm posted $1.80 EPS. The business's quarterly revenue was down 4.1% compared to the same quarter last year. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.